ARTICLE | Clinical News

Onyx gains on pivotal carfilzomib data

December 8, 2010 1:09 AM UTC

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) gained $3.95 (13%) to $33.29 on Tuesday after reporting final data from the pivotal Phase IIb PX-171-003-A1 trial of IV carfilzomib to treat relapsed and refractory multiple myeloma. The selective proteasome inhibitor led to a median overall survival of 15.5 months and produced an overall response rate of 24.1%, with a median duration of response of 8.3 months and a clinical benefit rate of 34.2%. Overall survival for responding patients has not yet been reached, but Onyx said it is expected to exceed 19 months. ...